细胞株Cell Lines 101及完全培养基-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心http://www.biovector.net
- 价 格：¥19200
- 货 号：NTCC-CV101
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
细胞株Cell Lines-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
ID SYF + c-Src
AC CVCL_8976
DR CLO; CLO_0009234
DR ATCC; CRL-2498
RX PubMed=10228160;
CC Knockout cell: Method=KO mouse; MGI; MGI:95602; Fyn.
CC Knockout cell: Method=KO mouse; MGI; MGI:98397; Src.
CC Knockout cell: Method=KO mouse; MGI; MGI:99147; Yes1.
CC Transfected with: MGI; MGI:98397; Src.
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_6461 ! SYF
CA Transformed cell line
//
ID SYM-I
AC CVCL_M718
RX PubMed=6208314;
CC From: Sekiguchi M.; Institute of Medical Science; University of Tokyo; Tokyo; Japan.
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID SYN-1
AC CVCL_W498
RX PubMed=12237927;
CC Derived from metastatic site: Lung.
DI NCIt; C3400; Synovial sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID SYNb-1
AC CVCL_W499
RX PubMed=12237927;
DI NCIt; C3400; Synovial sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W500 ! SYNb-2
SX Male
CA Cancer cell line
//
ID SYNb-2
AC CVCL_W500
RX PubMed=12237927;
CC Derived from metastatic site: Lung.
DI NCIt; C3400; Synovial sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W499 ! SYNb-1
SX Male
CA Cancer cell line
//
ID SYO-1
AC CVCL_7146
SY SYO-I
DR Cosmic; 1211854
DR Cosmic; 1319812
DR Cosmic; 2307725
DR GEO; GSM482570
DR GEO; GSM1676335
DR GEO; GSM1701667
RX PubMed=14744540;
RX PubMed=24726063;
RX PubMed=26351324;
DI NCIt; C4279; Biphasic synovial sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID SYSU-1
AC CVCL_C067
SY SYSUe001-A
DR hPSCreg; SYSUe001-A
DR ISCR; 1600
RX PubMed=17442208;
CC From: Sun Yat-sen University; Guangzhou; China.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SYSU-2
AC CVCL_C068
SY SYSUe002-A
DR hPSCreg; SYSUe002-A
DR ISCR; 1601
RX PubMed=17442208;
CC From: Sun Yat-sen University; Guangzhou; China.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-32
AC CVCL_M633
SY sz-32; CHL-5
DR IMGT/HLA; 16475
RX PubMed=19845917;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID SZ-BOR1
AC CVCL_Y322
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C98983; Melnick-Fraser syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-BRCA1
AC CVCL_Y323
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C36100; BRCA1 syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-CIPA1
AC CVCL_Y324
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C118633; Congenital insensitivity to pain with anhidrosis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-DM1
AC CVCL_Y325
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID SZ-DM2
AC CVCL_Y326
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-DM4
AC CVCL_Y327
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-DM5
AC CVCL_Y328
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID SZ-DM7
AC CVCL_Y329
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-FX1
AC CVCL_Y330
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-FX10
AC CVCL_Y331
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-FX2
AC CVCL_Y332
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID SZ-FX3
AC CVCL_Y333
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-FX5
AC CVCL_Y334
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-FX6
AC CVCL_Y335
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C84717; Fragile X syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID SZ-HED7
AC CVCL_Y336
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID SZ-Hun4
AC CVCL_Y337
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C61260; Hunter syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-Rb18
AC CVCL_Y338
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C7541; Retinoblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID SZ-Rb2
AC CVCL_Y339
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C7541; Retinoblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-Rb26
AC CVCL_Y340
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C7541; Retinoblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ-SBMA
AC CVCL_Y341
RX PubMed=21585244;
CC From: Shaare Zedek Medical Center; The Hebrew University; Jerusalem; Israel.
DI NCIt; C85233; X-linked bulbar-muscular atrophy
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID SZ95
AC CVCL_9803
SY SZ-95; SZ 95
DR BTO; BTO:0003484
RX PubMed=10594745;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID SZGSQ-12
AC CVCL_9T35
DR IMGT/HLA; 25445
RX PubMed=22077627;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID T HESCs
AC CVCL_C464
SY THESCs
DR ATCC; CRL-4003
DR BioSample; SAMN03471714
RX PubMed=14726435;
CC Transfected with: HGNC; 11730; TERT.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12,13
ST D16S539: 12,14
ST D5S818: 8
ST D7S820: 10
ST TH01: 7,8
ST TPOX: 9,11
ST vWA: 16,18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Telomerase immortalized cell line
//
ID T 174
AC CVCL_U955
DR ATCC; CRL-7726
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-7726; true.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 13
ST D16S539: 10,11
ST D5S818: 11
ST D7S820: 8,12
ST TH01: 9.3
ST TPOX: 9
ST vWA: 18
DI NCIt; C3359; Rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T-1
AC CVCL_M858
DR BioSample; SAMN03151761
RX CelloPub=CLPUB00262;
RX PubMed=7394535;
RX PubMed=13545791;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=7394535, PubMed=20143388). Originally thought to originate from the kidney of a 8-year old boy.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID T-1387
AC CVCL_F244
DR CLO; CLO_0009240
DR CLDB; cl4453
WW http://www.rccc.cytspb.rssi.ru/ecellbank/human/ht-1387.htm
DI NCIt; C3183; T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T-23
AC CVCL_5595
DR CLO; CLO_0050007
DR RCB; RCB1861
RX PubMed=3331674;
OX NCBI_TaxID=37347; ! Tupaia belangeri
SX Male
CA Finite cell line
//
ID T-23 clone 8
AC CVCL_5596
SY T-238
DR JCRB; JCRB0745
OX NCBI_TaxID=37347; ! Tupaia belangeri
HI CVCL_5595 ! T-23
SX Male
CA Finite cell line
//
ID T-289
AC CVCL_8760
SY 289
DR BTO; BTO:0004618
RX PubMed=3652009;
RX PubMed=8752169;
RX PubMed=10661763;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T-3-Cl-2
AC CVCL_4312
AS CVCL_F515
SY T-3-CI-2; T3-C12; T3-CI2; T3Cl2; T3CL2; GM00979
DR CLO; CLO_0029501
DR Coriell; GM00979
RX PubMed=1071084;
RX PubMed=4509323;
CC Breed/subspecies: DDD.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_1N76 ! TSFAT-3
SX Male
CA Cancer cell line
//
ID T-3-Cl-2-0.fl
AC CVCL_4313
SY T-3-CI-2-0.fl
DR CLO; CLO_0050784
DR ECACC; 99072804
DR RCB; RCB0561
CC Breed/subspecies: DDD.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4312 ! T-3-Cl-2
SX Male
CA Cancer cell line
//
ID T-33
AC CVCL_8427
DR BioSample; SAMN03151816
RX PubMed=3167860;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a K-562 derivative (PubMed=12592342, PubMed=20143388).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID T-47
AC CVCL_3945
SY T47
DR BTO; BTO:0003741
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T-47D
AC CVCL_0553
SY T-47-D; T47-D; T47D:A; T47D
DR BTO; BTO:0001248
DR CLO; CLO_0009251
DR EFO; EFO_0001247
DR MCCL; MCC:0000454
DR CLDB; cl4454
DR CLDB; cl4455
DR CLDB; cl4923
DR ATCC; HTB-133
DR BCRC; 60250
DR BCRJ; 0323
DR BioSample; SAMN03472872
DR CCLE; T47D_BREAST
DR CCRID; 3111C0001CCC000265
DR CCRID; 3131C0001000700087
DR CCRID; 3142C0001000000045
DR ChEMBL-Cells; CHEMBL3307606
DR ChEMBL-Targets; CHEMBL614361
DR CLS; 300353/p525_T-47D
DR Cosmic; 687500
DR Cosmic; 755296
DR Cosmic; 871150
DR Cosmic; 875882
DR Cosmic; 877451
DR Cosmic; 894091
DR Cosmic; 897428
DR Cosmic; 904395
DR Cosmic; 905945
DR Cosmic; 934538
DR Cosmic; 944295
DR Cosmic; 947353
DR Cosmic; 949193
DR Cosmic; 979711
DR Cosmic; 991330
DR Cosmic; 997925
DR Cosmic; 1000126
DR Cosmic; 1010918
DR Cosmic; 1017169
DR Cosmic; 1018470
DR Cosmic; 1019311
DR Cosmic; 1027050
DR Cosmic; 1044203
DR Cosmic; 1044220
DR Cosmic; 1046942
DR Cosmic; 1047715
DR Cosmic; 1092641
DR Cosmic; 1136342
DR Cosmic; 1152529
DR Cosmic; 1175835
DR Cosmic; 1176629
DR Cosmic; 1287901
DR Cosmic; 1289418
DR Cosmic; 1305387
DR Cosmic; 1308999
DR Cosmic; 1312373
DR Cosmic; 1434958
DR Cosmic; 1524350
DR Cosmic; 1565732
DR Cosmic; 1603226
DR Cosmic; 1609473
DR Cosmic; 1995658
DR Cosmic; 1998484
DR Cosmic; 2162162
DR Cosmic; 2165027
DR Cosmic; 2301534
DR Cosmic; 2318373
DR Cosmic; 2437466
DR Cosmic; 2564833
DR Cosmic-CLP; 905945
DR DSMZ; ACC-739
DR ECACC; 85102201
DR ENCODE; ENCBS323FFY
DR ENCODE; ENCBS440ENC
DR ENCODE; ENCBS441ENC
DR ENCODE; ENCBS442ENC
DR ENCODE; ENCBS597ENC
DR ENCODE; ENCBS598ENC
DR ENCODE; ENCBS599ENC
DR ENCODE; ENCBS600ENC
DR ENCODE; ENCBS601ENC
DR ENCODE; ENCBS602ENC
DR ENCODE; ENCBS603ENC
DR ENCODE; ENCBS604ENC
DR ENCODE; ENCBS610MSM
DR ENCODE; ENCBS620AAA
DR ENCODE; ENCBS622AAA
DR ENCODE; ENCBS624AAA
DR ENCODE; ENCBS625AAA
DR ENCODE; ENCBS626AAA
DR ENCODE; ENCBS627AAA
DR ENCODE; ENCBS805DMB
DR ENCODE; ENCBS943ULT
DR GDSC; 905945
DR GEO; GSM818
DR GEO; GSM50185
DR GEO; GSM50249
DR GEO; GSM69196
DR GEO; GSM73762
DR GEO; GSM115116
DR GEO; GSM149980
DR GEO; GSM149988
DR GEO; GSM149996
DR GEO; GSM186461
DR GEO; GSM186462
DR GEO; GSM186463
DR GEO; GSM217605
DR GEO; GSM344358
DR GEO; GSM344408
DR GEO; GSM350514
DR GEO; GSM378141
DR GEO; GSM388215
DR GEO; GSM459712
DR GEO; GSM481305
DR GEO; GSM559637
DR GEO; GSM750782
DR GEO; GSM783929
DR GEO; GSM799322
DR GEO; GSM799385
DR GEO; GSM816673
DR GEO; GSM827326
DR GEO; GSM847440
DR GEO; GSM847507
DR GEO; GSM847164
DR GEO; GSM844715
DR GEO; GSM844714
DR GEO; GSM844716
DR GEO; GSM887685
DR GEO; GSM888777
DR GEO; GSM923428
DR GEO; GSM923429
DR GEO; GSM923431
DR GEO; GSM923436
DR GEO; GSM967820
DR GEO; GSM1008576
DR GEO; GSM1008919
DR GEO; GSM1153391
DR GEO; GSM1181243
DR GEO; GSM1181259
DR GEO; GSM1214577
DR GEO; GSM1374950
DR GEO; GSM1374951
DR GEO; GSM1374952
DR GEO; GSM1401654
DR GEO; GSM1670521
DR GEO; GSM1833628
DR ICLC; HTL98003
DR KCB; KCB 2011116YJ
DR KCLB; 30133
DR LINCS; 50541
DR Lonza; 748
DR NCBI_Iran; C203
DR PRIDE; PXD002104
DR SKY/M-FISH/CGH; 2824
DR TOKU-E; 3260
DR TOKU-E; 3775
RX DOI=10.4172/2157-7145.S2-005;
RX PubMed=228940;
RX PubMed=2041050;
RX PubMed=8824553;
RX PubMed=9671407;
RX PubMed=10862037;
RX PubMed=11044355;
RX PubMed=11414198;
RX PubMed=12353263;
RX PubMed=12661003;
RX PubMed=12800145;
RX PubMed=15767549;
RX PubMed=17088437;
RX PubMed=17157791;
RX PubMed=17254797;
RX PubMed=19372543;
RX PubMed=19582160;
RX PubMed=19727395;
RX PubMed=20070913;
RX PubMed=21378333;
RX PubMed=22460905;
RX PubMed=23325432;
RX PubMed=23601657;
RX PubMed=23671654;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=5
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/t-47d.htm
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=T-47D
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/T47D_StamandMyers_protocol.pdf
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.addexbio.com/productdetail?pid=69
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-41.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 3.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: JFCR45 cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 1.6 days (PubMed=9671407); 45.5 hours (DTP); ~30-40 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'T470' in Cosmic 877451 and Cosmic 1152529.
CC Misspelling: 'T74D' in Cosmic 1027050.
CC Misspelling: 'T-47D-RU' in Cosmic 1175835.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 10
ST D18S51: 17
ST D19S433: 14
ST D21S11: 28,31
ST D2S1338: 24
ST D3S1358: 15,17
ST D5S818: 12
ST D7S820: 11
ST D8S1179: 13
ST FGA: 23
ST Penta D: 10,12
ST Penta E: 7,14
ST TH01: 6 (ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25877200)
ST TH01: 6,7 (CLS)
ST TPOX: 11
ST vWA: 14
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3945 ! T-47
SX Female
CA Cancer cell line
//
ID T-47D SimpleCell O-GalNAc
AC CVCL_S034
SY T47D SimpleCell; T47D SC
RX PubMed=23584533;
CC Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans.
CC Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T-47D Tet-On
AC CVCL_V334
WW http://www.clontech.com/US/Products/Inducible_Systems/Tetracycline-Inducible_Expression/Tet-On_Cell_Lines
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T-47D-Luc
AC CVCL_AS01
DR JCRB; JCRB1374
DR JCRB; NIHS0639
CC Problematic cell line: Possibly misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile).
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: JCRB; JCRB1374; probable.
CC Discontinued: JCRB; NIHS0639; true.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,11
ST D16S539: 12,13
ST D5S818: 13
ST D7S820: 10,12
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 18,19
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T-47Daro
AC CVCL_9582
RX PubMed=9449203;
CC Transfected with: HGNC; 2594; CYP19A1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T-88
AC CVCL_5369
SY T88
RX PubMed=2624778;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=T88
CC Characteristics: IL3 or IL5 dependent.
CC Caution: Not from strain DBA/2J as originally published but from strain C3H/He (DOI 10.4051/ibc.2010.2.4.0014).
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Factor-dependent cell line
//
ID T-9
AC CVCL_M092
SY T9
DR BioSample; SAMN03151762
RX PubMed=1246601;
RX PubMed=4472134;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=1246601, PubMed=4472134, PubMed=20143388).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID T-Ag-MOSE
AC CVCL_C562
DR JCRB; JCRB0151
DR JCRB; NIHS0214
RX PubMed=9820870;
CC Discontinued: JCRB; NIHS0214; true.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Transformed cell line
//
ID T-AL/N
AC CVCL_6334
SY T AL/N; TAL/N
DR CLO; CLO_0009266
DR ATCC; CRL-6514
RX PubMed=174816;
RX PubMed=4302577;
RX PubMed=4331720;
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6514; true.
CC Breed/subspecies: AL/N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_6312 ! AL/N
CA Spontaneously immortalized cell line
//
ID T-HEECs
AC CVCL_0F63
SY T HEECs; THEECs
DR ATCC; CRL-4026
DR BioSample; SAMN03471729
CC Transfected with: HGNC; 11730; TERT.
CC Discontinued: ATCC; CRL-4026; true.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8,10,12
ST D16S539: 9,12
ST D5S818: 11,12,13
ST D7S820: 9,10,11,12
ST TH01: 7,8,9
ST TPOX: 8,10
ST vWA: 14,15,18,19
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Telomerase immortalized cell line
//
ID T-HSC/Cl-6
AC CVCL_M083
DR BTO; BTO:0003527
RX PubMed=12753423;
RX PubMed=17760834;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: Sprague-Dawley.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Transformed cell line
//
ID t-HUE2
AC CVCL_J427
RX PubMed=1817644;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2029 ! ECV-304
SX Female
CA Cancer cell line
//
ID t-HUE4
AC CVCL_J428
RX PubMed=1817644;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2029 ! ECV-304
SX Female
CA Cancer cell line
//
ID T-REx-293
AC CVCL_D585
SY T-REx 293; HEK293-T-REx
DR BTO; BTO:0005238
WW http://www.thermofisher.com/order/catalog/product/R71007
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-410.html
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/T-REx-HEK293_Farnham_protocol.pdf
CC Part of: ENCODE project common cell types; tier 3.
CC Transformant: NCBI_TaxID; 28285; Adenovirus 5.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0045 ! HEK293
SX Female
CA Transformed cell line
//
ID T-REx-CHO
AC CVCL_D586
SY T-REx CHO
WW http://www.thermofisher.com/order/catalog/product/R71807
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-599.html
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0213 ! CHO
SX Female
CA Spontaneously immortalized cell line
//
ID T-REx-HeLa
AC CVCL_D587
SY T-REx HeLa; HeLa T-REx
DR TOKU-E; 3542
WW http://www.thermofisher.com/order/catalog/product/R71407
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-598.html
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID T-REx-Jurkat
AC CVCL_D588
SY T-REx Jurkat
WW http://www.thermofisher.com/order/catalog/product/R72207
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID T-YFP-SF1
AC CVCL_F703
RX PubMed=21959845;
CC Group: Cetacean cell line.
CC Doubling time: 27.27 hours (in 15% FBS), 29.4 hours (in 10% FBS) (PubMed=21959845).
CC Transfected with: UniProtKB; P42212; GFP.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: Asiaeorientalis.
OX NCBI_TaxID=34892; ! Neophocaena phocaenoides
HI CVCL_F702 ! YFP-SF1
SX Male
CA Transformed cell line
//
ID T.T
AC CVCL_3174
SY T-T; T_T_; T. T; tdott
DR BioSample; SAMN03470960
DR CCLE; TT_OESOPHAGUS
DR Cosmic; 923184
DR Cosmic-CLP; 1299064
DR GDSC; 1299064
DR GEO; GSM827520
DR GEO; GSM887713
DR GEO; GSM888806
DR GEO; GSM1670549
DR JCRB; JCRB0262
RX DOI=10.5794/jjoms.36.307;
RX PubMed=9290701;
RX PubMed=22460905;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 40 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Mandible.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 11,13
ST D13S317: 11
ST D16S539: 9,11
ST D18S51: 13,17
ST D19S433: 14,15
ST D21S11: 30
ST D2S1338: 24
ST D3S1358: 15
ST D5S818: 8,10
ST D7S820: 11
ST D8S1179: 15,16
ST FGA: 18
ST Penta D: 12
ST Penta E: 16,18
ST TH01: 9
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T.Tn
AC CVCL_3175
SY T_Tn; T-Tn; TTn; T Tn; T-Tn6; TTN
DR BioSample; SAMN03471669
DR Cosmic; 873391
DR Cosmic; 923185
DR Cosmic; 1612902
DR GEO; GSM827521
DR GEO; GSM1374967
DR JCRB; JCRB0261
RX DOI=10.5794/jjoms.36.307;
RX PubMed=9290701;
RX PubMed=15885884;
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Mandible.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,13
ST D13S317: 10,11
ST D16S539: 9,11
ST D5S818: 8,10
ST D7S820: 11
ST TH01: 9
ST TPOX: 8,11
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3174 ! T.T
SX Male
CA Cancer cell line
//
ID T/C28a2
AC CVCL_6850
SY T/C-28a2; TC28a2; C28A2; T/C-28
DR BTO; BTO:0003860
DR GEO; GSM297603
DR GEO; GSM297604
DR Lonza; 121
DR Millipore; SCC042
RX PubMed=7989586;
RX PubMed=14673991;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID T/C28a4
AC CVCL_M776
SY T/C-28a4
DR BTO; BTO:0005558
RX PubMed=14673991;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6850 ! T/C28a2
SX Female
CA Transformed cell line
//
ID T/G HA-VSMC
AC CVCL_4009
SY T/G HA VSMC; T/G HA-vSMC
DR BTO; BTO:0001962
DR CLO; CLO_0009237
DR CLDB; cl4470
DR ATCC; CRL-1999
DR BioSample; SAMN03471275
DR CCRID; 3142C0001000000058
DR ECACC; 94102702
DR IZSLER; BS CL 149
DR NCBI_Iran; C591
CC Discontinued: ECACC; 94102702; probable.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 11,12
ST D16S539: 12
ST D5S818: 12,13
ST D7S820: 9,10
ST TH01: 7,8
ST TPOX: 8
ST vWA: 16
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID T02J-10/10
AC CVCL_U010
SY CHO-GCGR
DR ECACC; 10031605
RX PubMed=21335600;
CC Transfected with: HGNC; 4192; GCGR.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID T02J-7/10
AC CVCL_U011
SY CHO-M3; CHO-CHRM3
DR ECACC; 10031603
RX PubMed=21335600;
CC Transfected with: HGNC; 1952; CHRM3.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID T02J-9/10
AC CVCL_U012
SY CHO-H2; CHO-HRH2
DR ECACC; 10031604
RX PubMed=21335600;
CC Transfected with: HGNC; 5183; HRH2.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID T1
AC CVCL_7904
SY T1 (174 x CEM.T1); T1(174 x CEM.T1); 174xCEM.T1; 174xCEM; CEMx174; CEM x 174
DR CLO; CLO_0009238
DR ATCC; CRL-1991
DR BioSample; SAMN03471270
DR NIH-ARP; 272-357
RX PubMed=3872841;
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,12
ST D16S539: 10,12
ST D5S818: 12,14
ST D7S820: 10,11,15
ST TH01: 6,9.3
ST TPOX: 8,12
ST vWA: 14,17
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6260 ! LCL 721.174
HI CVCL_7905 ! CEMR.3
CA Hybrid cell line
//
ID T1 [Human contaminated neural stem cell]
AC CVCL_1U15
DR BioSample; SAMN03151760
RX PubMed=21814484;
RX PubMed=22949886;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=22949886).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID T1-73
AC CVCL_3605
AS CVCL_1772
SY TI-73; T173
DR CLO; CLO_0009241
DR ATCC; CRL-7943
DR BioSample; SAMN03471127
DR CCLE; T173_BONE
DR ChEMBL-Cells; CHEMBL3308222
DR ChEMBL-Targets; CHEMBL2366158
DR Cosmic; 687932
DR Cosmic; 910696
DR GDSC; 910696
DR GEO; GSM185158
DR GEO; GSM185159
DR GEO; GSM827271
DR GEO; GSM887682
DR GEO; GSM888774
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 12
ST D5S818: 8,12
ST D7S820: 8,10
ST TH01: 9,9.3
ST TPOX: 8,9
ST vWA: 15,16
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N340 ! F1-73
CA Cancer cell line
//
ID T1-A
AC CVCL_6C57
RX PubMed=26254261;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Breed/subspecies: NIH Swiss.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_5845 ! NIH 3T3-ras
SX Male
CA Transformed cell line
//
ID T1.7
AC CVCL_K255
DR CLO; CLO_0050389
DR RCB; RCB2307
CC Monoclonal antibody target: UniProtKB; P18266; Rat Gsk3b.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T1/CUHK
AC CVCL_E317
RX PubMed=1280031;
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T1/HCVcon
AC CVCL_B334
RX PubMed=15914852;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7904 ! T1
CA Hybrid cell line
//
ID T1/NS3-4A
AC CVCL_B335
RX PubMed=15914852;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7904 ! T1
CA Hybrid cell line
//
ID T1000
AC CVCL_M809
RX PubMed=22911243;
DI NCIt; C4250; Well differentiated liposarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T101 [Mouse hybridoma against bladder carcinomas]
AC CVCL_N333
DR ATCC; HB-8273
RX Patent=US4643971;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T101 [Mouse hybridoma against human CD5]
AC CVCL_DC79
DR ATCC; CRL-8023
RX CelloPub=CLPUB00335;
RX Patent=US4675386;
RX PubMed=6993560;
CC Monoclonal antibody target: UniProtKB; P06127; Human CD5.
CC Anecdotal: The T101 mAb was one of the earliest mAbs to be tested in clinical trials against cutaneous T cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL).
CC Discontinued: ATCC; CRL-8023; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T101-iPSC
AC CVCL_DD61
RX PubMed=27191603;
ST Source(s): PubMed=27191603
ST Amelogenin: X,Y
ST CSF1PO: 10,14
ST D13S317: 9,11
ST D16S539: 12
ST D21S11: 28,31
ST D5S818: 11,12
ST D7S820: 10,11
ST TH01: 7,8
ST TPOX: 8
ST vWA: 16,17
DI NCIt; C26845; Parkinson's disease
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DD53 ! ND31630
SX Male
CA Induced pluripotent stem cell
//
ID T11
AC CVCL_8926
RX PubMed=19886054;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T110 [Human B-cell IHW]
AC CVCL_6G70
DR IMGT/HLA; 12647
RX PubMed=11782282;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID T110 [Mouse hybridoma]
AC CVCL_N334
DR ATCC; HB-8278
RX Patent=US4643971;
CC Discontinued: ATCC; HB-8278; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T1165
AC CVCL_6731
SY TEPC 1165
DR Lonza; 90
RX PubMed=3261383;
RX PubMed=3726549;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=T1165
CC Breed/subspecies: BALB/cAnPt.
DI NCIt; C21631; Mouse plasmacytoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID T11D7e2
AC CVCL_F769
SY T11D7
DR CLO; CLO_0009239
DR ATCC; TIB-103
DR BCRC; 60471
DR ECACC; 92021209
DR ECACC; 92021210
RX PubMed=393521;
CC Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.1).
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T138
AC CVCL_N335
DR ATCC; HB-8277
RX Patent=US4643971;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T14c
AC CVCL_HF47
RX PubMed=2583278;
CC Transformant: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Transformed cell line
//
ID T16
AC CVCL_N336
DR ATCC; HB-8279
RX Patent=US4643971;
RX Patent=US4935344;
CC Discontinued: ATCC; HB-8279; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T1682
AC CVCL_D023
DR GEO; GSM577205
RX PubMed=18360827;
DI NCIt; C3411; Thymoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T1889
AC CVCL_D024
SY TC1889; T-1889
DR Cosmic; 1498256
DR GEO; GSM577204
RX PubMed=18360827;
DI NCIt; C7569; Thymic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T1P26
AC CVCL_8333
RX PubMed=8125107;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8337 ! M4Beu
CA Cancer cell line
//
ID T1P26L
AC CVCL_8334
RX PubMed=11059782;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8333 ! T1P26
CA Cancer cell line
//
ID T1P26R
AC CVCL_8335
RX PubMed=11059782;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8333 ! T1P26
CA Cancer cell line
//
ID T2
AC CVCL_2211
SY T2 (174 x CEM.T2); T2(174 x CEM.T2); 174xCEM.T2; CEMx721.174.T2
DR BTO; BTO:0003771
DR CLO; CLO_0009242
DR CLO; CLO_0050160
DR ATCC; CRL-1992
DR BioSample; SAMN03471271
DR BioSample; SAMN03472034
DR DSMZ; ACC-598
DR NCBI_Iran; C509
DR RCB; RCB1932
DR TKG; TKG 0599
DR TOKU-E; 3251
RX PubMed=1373173;
RX PubMed=3872841;
CC Doubling time: ~40-60 hours (DSMZ).
ST Source(s): ATCC; DSMZ; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,12
ST D16S539: 10,12
ST D5S818: 12,14
ST D7S820: 10,11,15 (ATCC; DSMZ)
ST D7S820: 10,11 (RCB; TKG)
ST TH01: 6,7,9.3
ST TPOX: 8,12
ST vWA: 14,17,20 (ATCC; DSMZ; TKG)
ST vWA: 17,19 (RCB)
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7904 ! T1
CA Hybrid cell line
//
ID T2-A
AC CVCL_6C58
RX PubMed=26254261;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Breed/subspecies: NIH Swiss.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_6C57 ! T1-A
SX Male
CA Transformed cell line
//
ID T2.A3
AC CVCL_S602
SY T2-A3; T2/A3
CC Transfected with: HGNC; 4931; HLA-A (allele HLA-A3).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2211 ! T2
CA Hybrid cell line
//
ID T2.DR3
AC CVCL_9W17
SY T2/DR3; T2DR3
RX PubMed=1373173;
RX PubMed=7600288;
RX PubMed=8195723;
CC Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*03:01).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2211 ! T2
CA Hybrid cell line
//
ID T2.DR3/DM
AC CVCL_9W18
RX PubMed=7600288;
CC Transfected with: HGNC; 4934; HLA-DMA.
CC Transfected with: HGNC; 4935; HLA-DMB.
CC Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*03:01).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9W17 ! T2.DR3
CA Hybrid cell line
//
ID T2.DR4
AC CVCL_9W15
SY T2.DR4w4; T2-DR4; T2DR4
DR NCBI_Iran; C529
RX PubMed=8195723;
CC Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*04:01).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2211 ! T2
CA Hybrid cell line
//
ID T2.DR4/DM
AC CVCL_9W16
SY T2-DR4-DM; T2DR4.DM
CC Transfected with: HGNC; 4934; HLA-DMA.
CC Transfected with: HGNC; 4935; HLA-DMB.
CC Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*04:01).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9W15 ! T2.DR4
CA Hybrid cell line
//
ID T2/CUHK
AC CVCL_E318
RX PubMed=1280031;
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T201
AC CVCL_V486
RX PubMed=11251167;
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T21C1
AC CVCL_1E83
SY ND50026
DR NHCDR; ND50026
WW https://www.nimhgenetics.org/stem_cells/crm_lines.php
CC From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA.
DI NCIt; C2993; Down syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_X867 ! AG06872
SX Female
CA Induced pluripotent stem cell
//
ID T21C5
AC CVCL_1E84
SY ND50027
DR NHCDR; ND50027
WW https://www.nimhgenetics.org/stem_cells/crm_lines.php
CC From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA.
CC Characteristics: Lost the third copy of chromosome 21.
DI NCIt; C2993; Down syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_X867 ! AG06872
SX Female
CA Induced pluripotent stem cell
//
ID T222
AC CVCL_S811
DR ChEMBL-Cells; CHEMBL3307464
DR ChEMBL-Targets; CHEMBL614947
RX PubMed=6318979;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T23
AC CVCL_N337
DR ATCC; HB-8271
RX Patent=US4643971;
CC Discontinued: ATCC; HB-8271; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T235
AC CVCL_6478
SY ATC235
DR Cosmic; 1239957
DR Cosmic; 2054078
DR Cosmic; 2186781
RX PubMed=17406368;
RX PubMed=18713817;
RX PubMed=23833040;
ST Source(s): PubMed=18713817
ST Amelogenin: X
ST D13S317: 11,14
ST D18S51: 13,19
ST D21S11: 29
ST D3S1358: 14
ST D5S818: 9,12
ST D7S820: 8,10
ST D8S1179: 11,14
ST FGA: 21,23
ST vWA: 17,18
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T238
AC CVCL_6299
DR Cosmic; 1239958
DR Cosmic; 2036696
DR Cosmic; 2054089
DR Cosmic; 2186788
RX PubMed=17406368;
RX PubMed=18713817;
RX PubMed=23833040;
ST Source(s): PubMed=18713817
ST Amelogenin: X
ST D13S317: 12
ST D18S51: 10,17
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11
ST D7S820: 11,13
ST D8S1179: 12
ST FGA: 21,22
ST vWA: 16,17
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T24
AC CVCL_0554
SY T-24; T 24
DR BTO; BTO:0001345
DR CLO; CLO_0009235
DR CLO; CLO_0009245
DR CLO; CLO_0050843
DR CLO; CLO_0050844
DR EFO; EFO_0002864
DR MCCL; MCC:0000455
DR CLDB; cl4452
DR ATCC; HTB-4
DR BCRC; 60062
DR BCRJ; 0231
DR BioSample; SAMN03472744
DR BioSample; SAMN03473324
DR CCLE; T24_URINARY_TRACT
DR CCRID; 3111C0001CCC000295
DR CCRID; 3131C0001000700055
DR CCRID; 3142C0001000000076
DR ChEMBL-Cells; CHEMBL3307700
DR ChEMBL-Targets; CHEMBL614774
DR CLS; 300352/p619_T24
DR Cosmic; 716174
DR Cosmic; 724812
DR Cosmic; 755400
DR Cosmic; 845561
DR Cosmic; 846275
DR Cosmic; 925832
DR Cosmic; 928817
DR Cosmic; 943742
DR Cosmic; 1001664
DR Cosmic; 1016880
DR Cosmic; 1046673
DR Cosmic; 1285130
DR Cosmic; 1285985
DR Cosmic; 1302355
DR Cosmic; 1927302
DR Cosmic; 1938698
DR Cosmic; 2037960
DR Cosmic; 2050465
DR Cosmic; 2057459
DR Cosmic; 2444230
DR Cosmic-CLP; 724812
DR DSMZ; ACC-376
DR GDSC; 724812
DR GEO; GSM492493
DR GEO; GSM887683
DR GEO; GSM888775
DR GEO; GSM1374940
DR GEO; GSM1574571
DR GEO; GSM1670520
DR JCRB; JCRB0711
DR KCB; KCB 92027YJ
DR KCLB; 30004
DR LINCS; 50048
DR PRIDE; PXD003105
DR RCB; RCB0431
DR RCB; RCB2536
DR TKG; TKG 0443
DR TOKU-E; 3252
RX PubMed=833871;
RX PubMed=864752;
RX PubMed=2607719;
RX PubMed=3708594;
RX PubMed=4133950;
RX PubMed=6244232;
RX PubMed=6823318;
RX PubMed=6826254;
RX PubMed=7185004;
RX PubMed=8873383;
RX PubMed=9290701;
RX PubMed=16885334;
RX PubMed=19375735;
RX PubMed=22460905;
RX PubMed=23401075;
RX PubMed=24018021;
RX PubMed=24367658;
RX PubMed=25997541;
RX PubMed=26972028;
RX PubMed=27141528;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=T24
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-335.html
WW http://tcpaportal.org/mclp/
CC Part of: BLA-40 bladder carcinoma cell line panel.
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: UBC-40 urothelial bladder cancer cell line index.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: GPI-anchored proteins analysis by proteomics.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 10,12 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; TKG)
ST CSF1PO: 12 (RCB)
ST D13S317: 12 (ATCC; CLS; Cosmic-CLP; JCRB; KCLB; RCB; TKG)
ST D13S317: 9,12 (DSMZ)
ST D16S539: 9
ST D18S51: 16,18
ST D21S11: 29
ST D3S1358: 16,21 (CLS)
ST D3S1358: 16 (KCLB)
ST D5S818: 10,12 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; TKG)
ST D5S818: 10 (RCB)
ST D7S820: 10,11
ST D8S1179: 9,14 (CLS)
ST D8S1179: 14 (PubMed=11416159)
ST FGA: 17,22
ST Penta D: 11,15
ST Penta E: 7,10
ST TH01: 6
ST TPOX: 8,11
ST vWA: 17 (ATCC; Cosmic-CLP; JCRB; RCB; TKG)
ST vWA: 17,19 (CLS; DSMZ; KCLB; PubMed=11416159)
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T24/83
AC CVCL_2728
DR CLO; CLO_0009246
DR CLDB; cl4473
DR ECACC; 85061107
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID T24/DDP10
AC CVCL_Y181
DR CGH-DB; 9115-4
RX PubMed=8205547;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID T24/DDP5
AC CVCL_Y182
DR CGH-DB; 9113-4
RX PubMed=8205547;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID T24/DDP7
AC CVCL_Y183
DR CGH-DB; 9114-4
RX PubMed=8205547;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID T241
AC CVCL_M975
SY ATC241
DR Cosmic; 1239979
DR Cosmic; 2054112
DR Cosmic; 2186784
RX PubMed=17406368;
RX PubMed=23833040;
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T243
AC CVCL_M976
DR Cosmic; 2186785
RX PubMed=17406368;
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T24T
AC CVCL_M892
RX PubMed=10679914;
RX PubMed=12460916;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID T265
AC CVCL_S805
SY T265-2c; T265-2C; T265p21
DR EFO; EFO_0006304
DR Cosmic; 1644552
DR Cosmic; 1801808
DR Cosmic; 2307730
RX PubMed=9766530;
RX PubMed=16429615;
RX PubMed=16510576;
RX PubMed=21084276;
RX PubMed=22346343;
RX PubMed=24726063;
CC Omics: Transcriptome analysis.
DI NCIt; C3798; Malignant peripheral nerve sheath tumor
DI NCIt; C3273; Neurofibromatosis type 1
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T26J-1/09
AC CVCL_U013
SY CHO-Beta-2; CHO-ADRB2
DR ECACC; 10031601
RX PubMed=21335600;
CC Transfected with: HGNC; 286; ADRB2.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID T27A
AC CVCL_3606
DR CLO; CLO_0009247
DR ATCC; TIB-57
CC Breed/subspecies: BALB/c.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID T27A1
AC CVCL_AZ72
RX PubMed=7583324;
RX PubMed=10516297;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: PVG.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Transformed cell line
//
ID T29
AC CVCL_2G67
RX PubMed=14996724;
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5535 ! IOSE-29
SX Female
CA Telomerase immortalized cell line
//
ID T29/33
AC CVCL_DC80
DR ATCC; CRL-8036
RX Patent=US4582797;
RX PubMed=6968338;
CC Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45.
CC Discontinued: ATCC; CRL-8036; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4696 ! S194/5.XXO.BU.1
CA Hybridoma
//
ID T29H
AC CVCL_2G69
RX PubMed=14996724;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2G67 ! T29
SX Female
CA Telomerase immortalized cell line
//
ID T29K
AC CVCL_2G74
RX PubMed=14996724;
CC Transfected with: HGNC; 6407; KRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2G67 ! T29
SX Female
CA Telomerase immortalized cell line
//
ID T3-1C12
AC CVCL_J130
DR ATCC; HB-9030
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9030; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-1C9
AC CVCL_J131
DR ATCC; HB-9033
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9033; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-1D8
AC CVCL_J132
DR ATCC; HB-9032
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9032; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-1E10
AC CVCL_J133
DR ATCC; HB-9060
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9060; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-1E5
AC CVCL_J134
DR ATCC; HB-9029
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9029; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-1E7
AC CVCL_J135
DR ATCC; HB-9055
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9055; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2A9
AC CVCL_J136
DR ATCC; HB-9028
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9028; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2B1
AC CVCL_J137
DR ATCC; HB-9057
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9057; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2D2
AC CVCL_J138
DR ATCC; HB-9061
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9061; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2G4
AC CVCL_J139
DR ATCC; HB-9058
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9058; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2H5
AC CVCL_J140
DR ATCC; HB-9056
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9056; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-2H6
AC CVCL_J141
DR ATCC; HB-9062
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9062; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-3A1
AC CVCL_F770
SY 3A1
DR CLO; CLO_0009248
DR ATCC; HB-2
DR NCBI_Iran; H158
RX PubMed=6156457;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID T3-3F11
AC CVCL_J142
DR ATCC; HB-9059
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9059; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-3H1
AC CVCL_J143
DR ATCC; HB-9064
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9064; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-4A7
AC CVCL_J144
DR ATCC; HB-9063
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9063; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-4C11
AC CVCL_J145
DR ATCC; HB-9031
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9031; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-5E9
AC CVCL_G093
SY 5E9C11
DR CLO; CLO_0001436
DR ATCC; HB-21
RX PubMed=6787129;
CC Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID T3-8B8
AC CVCL_J146
DR ATCC; HB-9066
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9066; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-8F5
AC CVCL_J147
DR ATCC; HB-9067
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9067; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-9E7
AC CVCL_J148
DR ATCC; HB-9065
RX Patent=US5071759;
CC Discontinued: ATCC; HB-9065; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T3-HA
AC CVCL_6C59
RX PubMed=26254261;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Breed/subspecies: NIH Swiss.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_6C58 ! T2-A
SX Male
CA Transformed cell line
//
ID T3-HEP-W1
AC CVCL_4Z94
RX DOI=10.2957/kanzo.28.1135;
RX PubMed=3338696;
DI NCIt; C124251; Woodchuck hepatocellular carcinoma
OX NCBI_TaxID=9995; ! Marmota monax
SX Male
CA Cancer cell line
//
ID T34
AC CVCL_J352
RX PubMed=3261629;
DI NCIt; C3467; Cutaneous T-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T34-2
AC CVCL_AZ71
RX PubMed=7583324;
RX PubMed=10516297;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CFHB Wistar.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Transformed cell line
//
ID T351
AC CVCL_M977
DR Cosmic; 1239980
DR Cosmic; 2054118
DR Cosmic; 2186786
RX PubMed=17406368;
RX PubMed=23833040;
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T35J-5/09
AC CVCL_U014
SY CHO-FFAR3
DR ECACC; 10031602
CC Transfected with: HGNC; 4499; FFAR3.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID T36274
AC CVCL_6335
SY T3 6274
DR CLO; CLO_0009249
DR ATCC; CRL-2012
RX PubMed=2985973;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0361 ! JB6 Cl 30-7b
CA Transformed cell line
//
ID T37i
AC CVCL_S893
RX PubMed=9502766;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Transformed cell line
//
ID T3M-1
AC CVCL_8289
RX DOI=10.1016/B978-0-12-333530-2.50007-1;
RX PubMed=308840;
RX PubMed=2474371;
CC Doubling time: ~17 hours (PubMed=308840).
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8663 ! CJM [Human OCSCC]
SX Male
CA Cancer cell line
//
ID T3M-1 Cl-10
AC CVCL_8761
SY T3M-1 Clone10; T3M-1 clone-10
DR CLO; CLO_0050090
DR BioSample; SAMN03472203
DR Cosmic; 2009525
DR RCB; RCB1017
RX PubMed=14733907;
ST Source(s): RCB
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 10,11
ST D16S539: 9,12
ST D5S818: 10,13
ST D7S820: 12,13
ST TH01: 7,9
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8289 ! T3M-1
SX Male
CA Cancer cell line
//
ID T3M-1 Cl-2
AC CVCL_8762
SY T3M-1 Clone2; T3M-1 clone-2
DR CLO; CLO_0050091
DR BioSample; SAMN03472202
DR RCB; RCB1015
RX PubMed=14733907;
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11
ST D16S539: 9,12
ST D5S818: 10,13
ST D7S820: 12,13
ST TH01: 7,9
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8289 ! T3M-1
SX Male
CA Cancer cell line
//
ID T3M-10
AC CVCL_8067
SY T3M10
DR CLO; CLO_0050071
DR BioSample; SAMN03472206
DR CCLE; T3M10_LUNG
DR RCB; RCB1020
RX PubMed=6088016;
RX PubMed=6091874;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
ST Source(s): RCB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11
ST D16S539: 9,10
ST D5S818: 11
ST D7S820: 11,14
ST TH01: 6,9
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T3M-11
AC CVCL_8066
SY T3M11
DR CLO; CLO_0050046
DR BioSample; SAMN03472208
DR RCB; RCB1022
RX PubMed=6091874;
RX PubMed=7730145;
ST Source(s): RCB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 9,12
ST D16S539: 10,13
ST D5S818: 10,13
ST D7S820: 8,12
ST TH01: 6,7
ST TPOX: 8,9
ST vWA: 18
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T3M-12
AC CVCL_4058
SY T3M12
DR CLO; CLO_0050060
DR BioSample; SAMN03471951
DR RCB; RCB1019
DR RCB; RCB2281
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Partially contaminated. Some stocks (such as RCB1019) were contaminated by T3M-1 (PubMed=20143388).
CC Discontinued: RCB; RCB1019; true.
ST Source(s): RCB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 13
ST D16S539: 9,11
ST D5S818: 11
ST D7S820: 10,11
ST TH01: 7
ST TPOX: 8
ST vWA: 15,16
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T3M-15
AC CVCL_Y007
RX PubMed=6091874;
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T3M-3
AC CVCL_8065
SY T3M3
DR CLO; CLO_0050641
DR BioSample; SAMN03472204
DR RCB; RCB1018
RX PubMed=6603906;
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D16S539: 9,12
ST D5S818: 11
ST D7S820: 10
ST TH01: 6,8
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C4646; Gestational choriocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T3M-4
AC CVCL_4056
SY T3M4; Panc89; Panc-89; PANC-89; Panc 89
DR BTO; BTO:0002864
DR CLO; CLO_0050113
DR EFO; EFO_0002714
DR BioSample; SAMN03472207
DR CCLE; T3M4_PANCREAS
DR Cosmic; 710873
DR Cosmic; 724641
DR Cosmic; 736281
DR Cosmic; 922257
DR Cosmic; 922263
DR Cosmic; 933528
DR Cosmic; 2546061
DR Cosmic; 2546062
DR GEO; GSM887684
DR GEO; GSM888776
DR GEO; GSM1374814
DR GEO; GSM1374815
DR GEO; GSM1374816
DR RCB; RCB1021
RX PubMed=6821838;
RX PubMed=11169959;
RX PubMed=11787853;
RX PubMed=12692724;
RX PubMed=22460905;
WW http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/T3M-4.html
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: KuDOS 95 cell line panel.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 10,13
ST D16S539: 11,12
ST D5S818: 11
ST D7S820: 12
ST TH01: 9.3
ST TPOX: 11,12
ST vWA: 18,19,21
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T3M-5
AC CVCL_8064
SY T3M5
DR CLO; CLO_0050948
DR BioSample; SAMN03472201
DR Cosmic; 2009526
DR RCB; RCB1012
RX PubMed=6982994;
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 12,13
ST D16S539: 10,12
ST D5S818: 11,13
ST D7S820: 13
ST TH01: 6,7
ST TPOX: 9,11
ST vWA: 16,17
DI NCIt; C46008; Thyroid gland squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T4 clone 3
AC CVCL_DA07
DR ATCC; HB-8499
RX Patent=US4636478;
CC Monoclonal antibody target: ChEBI; CHEBI:18332; L-thyroxine.
CC Discontinued: ATCC; HB-8499; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T4 Clone 5 (10-0101, 0062-83)
AC CVCL_F771
DR CLO; CLO_0009250
DR ATCC; HB-8500
RX Patent=US4636478;
CC Monoclonal antibody target: ChEBI; CHEBI:18332; L-thyroxine.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID T4-4
AC CVCL_0E54
RX PubMed=11904297;
CC Transfected with: HGNC; 11730; TERT.
CC Breed/subspecies: Sprague-Dawley.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Telomerase immortalized cell line
//
ID T4-PA
AC CVCL_6C60
RX PubMed=26254261;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Breed/subspecies: NIH Swiss.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_6C59 ! T3-HA
SX Male
CA Transformed cell line
//
ID T404
AC CVCL_1T20
DR BioSample; SAMN03151954
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764).
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 12
ST D16S539: 8,9
ST D5S818: 12
ST D7S820: 10
ST TH01: 8
ST TPOX: 10,11
ST vWA: 15,16
DI NCIt; C34447; Head and neck squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1T19 ! T406 [Human HNSCC]
OI CVCL_4910 ! Tu 138
OI CVCL_1T17 ! Tu 158LN
OI CVCL_4911 ! Tu 159
OI CVCL_4914 ! Tu 182
OI CVCL_4915 ! Tu 212
OI CVCL_1T18 ! Tu 212LN
CA Cancer cell line
//
ID T406 [Human glioblastoma]
AC CVCL_4570
SY T-406
DR CLS; 300361/NA
RX PubMed=3759084;
CC Discontinued: CLS; 300361; true.
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T406 [Human HNSCC]
AC CVCL_1T19
DR BioSample; SAMN03151955
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764).
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 12
ST D16S539: 8,9
ST D5S818: 12
ST D7S820: 10
ST TH01: 8
ST TPOX: 10,11
ST vWA: 15,16
DI NCIt; C34447; Head and neck squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1T20 ! T404
OI CVCL_4910 ! Tu 138
OI CVCL_1T17 ! Tu 158LN
OI CVCL_4911 ! Tu 159
OI CVCL_4914 ! Tu 182
OI CVCL_4915 ! Tu 212
OI CVCL_1T18 ! Tu 212LN
CA Cancer cell line
//
ID T409
AC CVCL_1Q88
SY T-409
DR BioSample; SAMN03151991
DR Cosmic; 1530764
RX PubMed=18234965;
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a UM-SCC-1 derivative (PubMed=21868764).
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,11
ST D16S539: 12,13
ST D5S818: 10,13
ST D7S820: 9,12
ST TH01: 6
ST TPOX: 8,11
ST vWA: 15,18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7707 ! UM-SCC-1
SX Male
CA Cancer cell line
//
ID T43
AC CVCL_N338
DR ATCC; HB-8275
RX Patent=US4643971;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T449
AC CVCL_M807
SY 93449; LPS449
DR Cosmic; 2307716
DR TOKU-E; 4077
RX PubMed=17354236;
RX PubMed=22911243;
RX PubMed=24726063;
DI NCIt; C4250; Well differentiated liposarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M808 ! T778
SX Female
CA Cancer cell line
//
ID T47D-E2J
AC CVCL_HG14
SY T47D E2J; E2J
DR Ximbio; 153169
RX PubMed=11118434;
RX PubMed=16319059;
CC Transfected with: HGNC; 4203; GCNT1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D-KBluc
AC CVCL_K229
SY T47DKBluc; T47DKBLUC
DR ATCC; CRL-2865
DR LINCS; 51091
RX PubMed=15166400;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 10
ST D5S818: 12
ST D7S820: 11
ST TH01: 6
ST TPOX: 11
ST vWA: 14
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D-ST3
AC CVCL_HG15
SY T47D 3STMYC
RX PubMed=9182658;
RX PubMed=16319059;
CC Transfected with: HGNC; 10862; ST3GAL1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D-ST3-STn
AC CVCL_HG17
RX PubMed=16319059;
CC Transfected with: HGNC; 10862; ST3GAL1.
CC Transfected with: HGNC; 23614; ST6GALNAC1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_HG15 ! T47D-ST3
SX Female
CA Cancer cell line
//
ID T47D-StN
AC CVCL_HG16
SY T47D-E2J-StN
DR Ximbio; 153170
RX PubMed=16319059;
CC Transfected with: HGNC; 4203; GCNT1.
CC Transfected with: HGNC; 23614; ST6GALNAC1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_HG14 ! T47D-E2J
SX Female
CA Cancer cell line
//
ID T47D-Y
AC CVCL_1H30
DR TOKU-E; 3661
RX PubMed=8033109;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D-YA
AC CVCL_1H31
RX PubMed=8033109;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1H30 ! T47D-Y
SX Female
CA Cancer cell line
//
ID T47D-YB
AC CVCL_1H32
RX PubMed=8033109;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1H30 ! T47D-Y
SX Female
CA Cancer cell line
//
ID T47D/182R-1
AC CVCL_1D34
SY T47D-182R1; 182R-1
DR Ximbio; 151891
RX PubMed=24513268;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D46 ! T47D/S5
SX Female
CA Cancer cell line
//
ID T47D/182R-2
AC CVCL_1D35
SY T47D-182R2; 182R-2
DR Ximbio; 151890
RX PubMed=24513268;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D46 ! T47D/S5
SX Female
CA Cancer cell line
//
ID T47D/A1-2
AC CVCL_0I95
SY T47D(A1-2); A1-2
RX PubMed=2550815;
CC Transfected with: RGD; 2741; Nr3c1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D/S2
AC CVCL_1D45
DR ECACC; 16022512
DR Ximbio; 152109
RX PubMed=25362855;
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 10
ST D18S51: 17
ST D21S11: 28,31
ST D5S818: 12
ST D7S820: 11
ST D8S1179: 13
ST FGA: 23
ST Penta D: 10,12
ST Penta E: 7,14
ST TH01: 6
ST TPOX: 11
ST vWA: 14
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D/S5
AC CVCL_1D46
DR Ximbio; 152111
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D/TR-1
AC CVCL_1D36
DR ECACC; 16022513
DR Ximbio; 152108
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 10
ST D18S51: 17
ST D21S11: 28,31
ST D5S818: 12
ST D7S820: 11
ST D8S1179: 13
ST FGA: 23
ST Penta D: 10,12
ST Penta E: 7,14
ST TH01: 6
ST TPOX: 11
ST vWA: 14
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D45 ! T47D/S2
SX Female
CA Cancer cell line
//
ID T47D/TR-2
AC CVCL_1D37
DR Ximbio; 152110
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D45 ! T47D/S2
SX Female
CA Cancer cell line
//
ID T47D:A18
AC CVCL_GY01
SY A18
RX PubMed=2224859;
RX PubMed=8883409;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D:C4
AC CVCL_GY02
RX PubMed=2224859;
RX PubMed=2632259;
RX PubMed=8883409;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0553 ! T-47D
SX Female
CA Cancer cell line
//
ID T47D:C4:2
AC CVCL_GY03
SY T47D:C42; T47DC42; C4:2
DR TOKU-E; 4085
RX PubMed=8883409;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_GY02 ! T47D:C4
SX Female
CA Cancer cell line
//
ID T5-1
AC CVCL_E839
AS CVCL_H270
SY T5-1 (3.1.0); T51; T51 LCL
DR dbMHC; 49031
DR ECACC; 94071434
DR IHW; IHW9284
DR IMGT/HLA; 11419
RX PubMed=75508;
WW http://bioinformatics.hsanmartino.it/ecbr/cl284.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID T508
AC CVCL_W136
RX PubMed=3759084;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T529-15D3-18-1A3-1B7
AC CVCL_F773
SY 1B7; 41.6-1B7; CTCC 10752
DR CLO; CLO_0009252
DR ATCC; HB-10500
RX Patent=US5959084;
RX Patent=US6143873;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F772 ! 443-15D3-2F12
HI CVCL_J227 ! 3G8 [Mouse hybridoma against human CD16]
CA Hybridoma
//
ID T529-15D3-2E5-4G12-1
AC CVCL_F774
SY 1A7; 34.5-1A7; CTCC 10753
DR CLO; CLO_0009253
DR ATCC; HB-10501
RX Patent=US5959084;
RX Patent=US6143873;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F772 ! 443-15D3-2F12
HI CVCL_J227 ! 3G8 [Mouse hybridoma against human CD16]
CA Hybridoma
//
ID T560
AC CVCL_F724
RX PubMed=1535783;
CC Breed/subspecies: B10 x B10.H-2aH-4b.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID T56/14
AC CVCL_DC69
DR ATCC; CRL-8035
RX Patent=US4626507;
RX PubMed=6265934;
CC Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71.
CC Discontinued: ATCC; CRL-8035; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4696 ! S194/5.XXO.BU.1
CA Hybridoma
//
ID T560.1
AC CVCL_F725
RX PubMed=1535783;
CC Breed/subspecies: B10 x B10.H-2aH-4b.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F724 ! T560
CA Cancer cell line
//
ID T560.2
AC CVCL_F726
RX PubMed=1535783;
CC Breed/subspecies: B10 x B10.H-2aH-4b.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F724 ! T560
CA Cancer cell line
//
ID T560.2.F7
AC CVCL_F727
RX PubMed=1535783;
CC Breed/subspecies: B10 x B10.H-2aH-4b.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F726 ! T560.2
CA Cancer cell line
//
ID T560.2.G4
AC CVCL_F728
RX PubMed=1535783;
CC Breed/subspecies: B10 x B10.H-2aH-4b.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F726 ! T560.2
CA Cancer cell line
//
ID T567
AC CVCL_W135
RX PubMed=3759084;
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T61577
AC CVCL_J123
RX PubMed=7448785;
CC Transformant: ChEBI; CHEBI:91112; N-butyl-N-(3-carboxypropyl)nitrosamine (BCPN).
CC Breed/subspecies: ACI.
DI NCIt; C60691; Rat urinary system neoplasms
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Cancer cell line
//
ID T67
AC CVCL_M033
RX PubMed=3485879;
RX PubMed=7519632;
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T7
AC CVCL_4314
DR ECACC; 07021402
RX PubMed=10949996;
CC Characteristics: Proliferates at permissive temperature (33-35 Celsius) in the presence of IFNG, terminally differentiates at restrictive temperature (39 Celsius) in the absence of IFNG.
CC Doubling time: 48 hours (ECACC).
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID T70
AC CVCL_M034
RX PubMed=3485879;
RX PubMed=7519632;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T705
AC CVCL_W137
RX PubMed=3759084;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T7526
AC CVCL_E840
DR dbMHC; 49032
DR ECACC; 94082238
DR IHW; IHW9076
DR IMGT/HLA; 11420
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl76.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID T7527
AC CVCL_E841
DR dbMHC; 49033
DR ECACC; 94070716
DR IHW; IHW9077
DR IMGT/HLA; 11421
WW http://bioinformatics.hsanmartino.it/ecbr/cl77.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID T778
AC CVCL_M808
SY 94778; 778
DR Cosmic; 2307717
RX PubMed=17354236;
RX PubMed=22911243;
RX PubMed=24726063;
DI NCIt; C4250; Well differentiated liposarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M807 ! T449
SX Female
CA Cancer cell line
//
ID T78-1
AC CVCL_X527
SY V79puro
DR ChEMBL-Cells; CHEMBL3307256
DR ChEMBL-Targets; CHEMBL613095
RX PubMed=9111301;
RX PubMed=14997211;
CC Transfected with: UniProtKB; P38489; E.coli nitroreductase nfnB.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_2234 ! V79
SX Male
CA Spontaneously immortalized cell line
//
ID T79-A3
AC CVCL_X528
SY V79-NTRpuro
RX PubMed=9111301;
RX PubMed=14997211;
CC Transfected with: UniProtKB; P38489; E.coli nitroreductase nfnB.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_2234 ! V79
SX Male
CA Spontaneously immortalized cell line
//
ID T80
AC CVCL_2G68
RX PubMed=14996724;
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5546 ! IOSE-80
SX Female
CA Telomerase immortalized cell line
//
ID T80-4
AC CVCL_5631
RX PubMed=6504058;
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_5634 ! Don D-6
SX Male
CA Spontaneously immortalized cell line
//
ID T80-6
AC CVCL_5632
RX PubMed=6504058;
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_5634 ! Don D-6
SX Male
CA Spontaneously immortalized cell line
//
ID T80-7
AC CVCL_5633
RX PubMed=6504058;
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_5634 ! Don D-6
SX Male
CA Spontaneously immortalized cell line
//
ID T80H
AC CVCL_2G70
RX PubMed=14996724;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2G68 ! T80
SX Female
CA Telomerase immortalized cell line
//
ID T80K
AC CVCL_2G75
RX PubMed=14996724;
CC Transfected with: HGNC; 6407; KRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2G68 ! T80
SX Female
CA Telomerase immortalized cell line
//
ID T84
AC CVCL_0555
SY T-84; T 84
DR BTO; BTO:0002032
DR CLO; CLO_0009254
DR EFO; EFO_0002084
DR MCCL; MCC:0000456
DR CLDB; cl4474
DR CLDB; cl4475
DR ATCC; CCL-248
DR BCRC; 60149
DR BCRJ; 0232
DR BioSample; SAMN03471378
DR BioSample; SAMN03473196
DR CCLE; T84_LARGE_INTESTINE
DR CCRID; 3111C0001CCC000056
DR CCRID; 3131C0001001200009
DR ChEMBL-Cells; CHEMBL3307275
DR ChEMBL-Targets; CHEMBL613531
DR CLS; 300354/p479_T84
DR Cosmic; 887245
DR Cosmic; 889532
DR Cosmic; 909761
DR Cosmic; 983742
DR Cosmic; 995406
DR Cosmic; 1043832
DR Cosmic; 1122335
DR Cosmic; 1184103
DR Cosmic; 1187325
DR Cosmic; 1479590
DR Cosmic; 1537487
DR Cosmic; 1609494
DR Cosmic; 1676743
DR Cosmic; 1708411
DR Cosmic; 1803953
DR Cosmic; 1888953
DR Cosmic; 2301548
DR Cosmic; 2302022
DR Cosmic-CLP; 909761
DR ECACC; 88021101
DR GDSC; 909761
DR GEO; GSM206556
DR GEO; GSM741255
DR GEO; GSM827303
DR GEO; GSM887686
DR GEO; GSM888778
DR GEO; GSM1346895
DR GEO; GSM1374953
DR GEO; GSM1448090
DR GEO; GSM1670522
DR ICLC; HTL95022
DR IGRhCellID; T84
DR IZSLER; BS TCL 154
DR SKY/M-FISH/CGH; 2853
RX PubMed=2110452;
RX PubMed=10612807;
RX PubMed=10737795;
RX PubMed=19927377;
RX PubMed=20606684;
RX PubMed=22460905;
RX PubMed=24755471;
RX PubMed=25485619;
RX PubMed=25926053;
RX PubMed=26537799;
RX PubMed=27397505;
WW http://www.addexbio.com/productdetail?pid=70
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep glycome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Lung.
ST Source(s): ATCC; CLS; Cosmic-CLP; ECACC; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9
ST D16S539: 10,11
ST D18S51: 17
ST D21S11: 31
ST D3S1358: 19
ST D5S818: 12
ST D7S820: 8,10
ST D8S1179: 15
ST FGA: 24
ST Penta D: 9
ST Penta E: 14
ST TH01: 6,9
ST TPOX: 8,11 (ATCC; Cosmic-CLP)
ST TPOX: 8 (CLS; ECACC; PubMed=25877200)
ST vWA: 17,18
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T84.66A3.1A.1F2
AC CVCL_F775
SY T84.66.A3.1-H-11
DR CLO; CLO_0009255
DR ATCC; HB-8747
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID T87
AC CVCL_N339
DR ATCC; HB-8274
RX Patent=US4643971;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID T87/rc
AC CVCL_M671
RX PubMed=1692307;
DI NCIt; C34447; Head and neck squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T88-M
AC CVCL_6542
SY T88M
DR CLO; CLO_0051533
DR RCB; RCB0792
RX DOI=10.4051/ibc.2010.2.4.0014;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=T88-M
CC Characteristics: IL3 or IL5 dependent.
CC Caution: Not from strain DBA/2J as originally published but from strain C3H/He (DOI 10.4051/ibc.2010.2.4.0014).
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_5369 ! T-88
SX Female
CA Factor-dependent cell line
//
ID T921
AC CVCL_T057
RX PubMed=23813186;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID T95-45D
AC CVCL_M081
RX PubMed=12209986;
CC From: Center for Medical Genetics; Ghent; Belgium.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID T98
AC CVCL_B368
SY T-98
RX PubMed=222778;
RX PubMed=833871;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID T98G
AC CVCL_0556
SY T 98 G; T-98G; T98 G; T98-G
DR BTO; BTO:0001583
DR CLO; CLO_0009236
DR CLO; CLO_0009258
DR CLO; CLO_0050636
DR EFO; EFO_0002085
DR MCCL; MCC:0000457
DR CLDB; cl4478
DR CLDB; cl4480
DR CLDB; cl4481
DR CLDB; cl4482
DR ATCC; CRL-1690
DR BioSample; SAMN01821603
DR BioSample; SAMN01821719
DR BioSample; SAMN01821740
DR BioSample; SAMN03473051
DR CCLE; T98G_CENTRAL_NERVOUS_SYSTEM
DR CGH-DB; 154-1
DR ChEMBL-Cells; CHEMBL3307777
DR ChEMBL-Targets; CHEMBL614775
DR Cosmic; 687586
DR Cosmic; 759898
DR Cosmic; 849847
DR Cosmic; 850740
DR Cosmic; 897444
DR Cosmic; 1175821
DR Cosmic; 1217675
DR Cosmic; 1294953
DR Cosmic; 1610748
DR Cosmic; 1746960
DR Cosmic; 2302325
DR Cosmic; 2367552
DR Cosmic; 2491103
DR Cosmic; 2516040
DR Cosmic-CLP; 687586
DR ECACC; 92090213
DR GDSC; 687586
DR GEO; GSM326205
DR GEO; GSM887687
DR GEO; GSM888779
DR GEO; GSM1374954
DR GEO; GSM1670523
DR IFO; IFO50303
DR IZSLER; BS TCL 63
DR JCRB; JCRB9041
DR KCLB; 21690
DR PRIDE; PXD000589
DR PRIDE; PXD002192
DR RCB; RCB1954
DR TKG; TKG 0471
RX PubMed=222778;
RX PubMed=3413074;
RX PubMed=11414198;
RX PubMed=16232199;
RX PubMed=18445040;
RX PubMed=19435942;
RX PubMed=22460905;
RX PubMed=22570425;
RX PubMed=25485619;
RX PubMed=25894527;
RX PubMed=25984343;
RX PubMed=26496030;
RX PubMed=27397505;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-574.html
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 3.
CC Characteristics: Has no IDH1 mutation.
CC Doubling time: 40 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Cell surface proteome.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; COG; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=22570425; PubMed=25877200; RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 13
ST D16S539: 13
ST D18S51: 13,16
ST D19S433: 12,13
ST D21S11: 28,32.2
ST D2S1338: 19,24
ST D3S1358: 16
ST D5S818: 10,12
ST D7S820: 9,10
ST D8S1179: 13,14
ST FGA: 21,22 (COG; KCLB)
ST FGA: 21 (PubMed=22570425; PubMed=25877200)
ST Penta D: 10,11
ST Penta E: 16
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 17,20
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B368 ! T98
SX Male
CA Cancer cell line
//
ID TA 99
AC CVCL_F776
SY TA99
DR CLO; CLO_0009259
DR ATCC; HB-8704
RX Patent=US5160723;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID TA-1
AC CVCL_F777
DR CLO; CLO_0009260
DR ATCC; HB-10206
RX Patent=US5604107;
CC Monoclonal antibody target: UniProtKB; P04626; Human ERBB2.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
- 公告/新闻
